RECOVERY & TISSUE REPAIR / MATRIX
Seven Compounds, One Comparison Table
How BPC-157, TB-500, GHK-Cu, KPV, and the three blends built from them differ in mechanism, evidence quality, and what's actually been proven in people.
The short version
This page lines up all seven compounds tracked on this site — BPC-157, TB-500, GHK-Cu, KPV, and the three blends built from them, Wolverine, KLOW, and GLOW — on the dimensions that actually matter for judging repair-peptide research: what each is chemically, what it's mechanistically supposed to do, how much human evidence actually exists, and the single biggest caution for each.
The honest headline: evidence quality varies enormously across these seven, from GHK-Cu's genuine controlled human clinical trials down to KPV's zero human studies of any kind, and all three blends share the identical, most important caveat: none has ever been tested as a combined product, no matter how often research-community marketing implies otherwise. None of this is medical advice, and no human dose is recommended anywhere on this page.
The comparison matrix
| Dimension | BPC-157 | TB-500 | GHK-Cu | KPV | Wolverine | KLOW | GLOW |
|---|---|---|---|---|---|---|---|
| What it is | 15-amino-acid gastric-derived peptide | 7-amino-acid fragment of thymosin beta-4 | Copper-chelated tripeptide | 3-amino-acid fragment of alpha-MSH | BPC-157 + TB-500 blend | KPV + GHK-Cu + BPC-157 + TB-500 blend | GHK-Cu + BPC-157 + TB-500 blend |
| Core mechanism | VEGFR2-driven angiogenesis [4] | Actin sequestration / cell migration [10] | Matrix synthesis + broad gene modulation [14] | NF-kB suppression via PepT1 uptake [20] | Angiogenesis + cell migration (extrapolated) | All four mechanisms (extrapolated) | Matrix + angiogenesis + migration (extrapolated) |
| Human evidence | 3 small pilot studies [2] | 0 trials of the fragment; Phase 1 data on full-length protein only [11] | Multiple controlled topical trials [13][16] | 0 human studies of any kind | 0 combination studies [23] | 0 combination studies | 0 combination studies |
| Regulatory status | Unapproved; WADA-prohibited | Unapproved; WADA-prohibited | Topical form legal cosmetic ingredient; injectable form unapproved | Unapproved research chemical | Unapproved; WADA-prohibited (both ingredients) | Unapproved; WADA-prohibited (TB-500 component) | Unapproved; WADA-prohibited (TB-500 component) |
| Key caution | Human evidence extremely thin [2] | Fragment is not the studied full-length protein [10] | Injectable use unstudied; topical form has the trial data [13] | Zero human data of any kind | Untested combination [23] | Untested combination; PK mismatch | Untested combination; largest copper load |
Mechanism, side by side
The four single compounds occupy genuinely different corners of the repair process, which is exactly why the research community keeps combining them. BPC-157's best-supported mechanism is angiogenesis, new blood-vessel growth via the VEGFR2-Akt-eNOS pathway [4]. TB-500's parent protein works inside the cell, sequestering actin to enable migration [10]. GHK-Cu acts at the genome and matrix level, shifting roughly 31% of measured gene expression toward repair and antioxidant programs while directly stimulating collagen and elastin synthesis [14]. KPV suppresses inflammatory transcription, NF-kB, and gets preferentially delivered to inflamed gut tissue [20].
The three blends are attempts to stack these mechanisms: Wolverine covers vessels plus migration; KLOW adds inflammation-suppression and matrix-building to that pair; GLOW swaps the inflammation piece for a bigger matrix-building dose. Mechanistically, the logic holds together on paper. What's missing from every blend is a study that actually tested the combination rather than assuming the individual mechanisms simply add up.
Evidence quality
This is where the seven genuinely separate. GHK-Cu has the deepest human evidence: multiple controlled topical trials measuring collagen synthesis and skin firmness, plus a 45-person randomized hair-growth trial with a statistically significant result [13][15][16]. BPC-157 sits in the middle, a 2025 review counts exactly three small human pilot studies, none large or controlled enough to establish efficacy [2]. TB-500 is thinner still: zero completed controlled trials of the fragment itself, with the encouraging human safety data belonging to the much larger full-length parent protein instead [11]. KPV has the least of all: no human studies whatsoever, animal and cell-culture data only [20].
The three blends inherit whichever ingredient is weakest, then add a further gap on top: none has ever been tested as a combination. A 2025 systematic review of BPC-157 in sports medicine, covering 36 studies, doesn't mention TB-500 or any combination at all, direct evidence that the Wolverine pairing, and by extension KLOW and GLOW, has simply never been put to a test [23].
Regulatory and safety status
BPC-157 and TB-500 share the same regulatory footprint: neither is FDA-approved, both are prohibited in competitive sport by the World Anti-Doping Agency, and both are sold strictly as research chemicals [8]. GHK-Cu splits by route: the topical cosmetic form, Copper Tripeptide-1, is a legal, widely marketed ingredient with a long safety record, while the injectable, systemic form used in research communities is unapproved and essentially unstudied in humans [13]. KPV has no cosmetic or approved-use pathway at all; it is a pure research chemical.
Because TB-500 is one ingredient in all three blends, every blend inherits the WADA-prohibited status regardless of the other ingredients [8]. KLOW carries the largest theoretical copper-accumulation concern, since GHK-Cu is its dominant ingredient by weight; GLOW carries a similar, somewhat smaller version of the same concern. None of the seven compounds has been studied in pregnancy, breastfeeding, or children.
The single biggest caution for each
For BPC-157, it's the sheer thinness of the human record, three pilot studies against a mountain of rodent data, from a literature concentrated in one research group [2]. For TB-500, it's identity: the fragment sold isn't the same molecule as the full-length protein most of the encouraging data describes [10]. For GHK-Cu, it's route, genuine trial data for topical use, essentially none for the injectable use some research communities describe. For KPV, it's simply the absence of any human evidence at all. For all three blends, Wolverine, KLOW, and GLOW, it's the same caution repeated three times: whatever is known about the ingredients individually, nothing is known about them combined, and the marketing language of synergy has outrun the science by a wide margin.